Precision BioSciences, Inc. - DTIL STOCK NEWS

Atomwise, a leader in AI-driven small molecule drug discovery, has appointed David Thomson, Ph.D., as Chief Scientific Officer, alongside Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D., as General Counsel. Dr. Thomson will spearhead the company's drug development strategy, focusing on enhancing their small molecule pipeline. His extensive experience includes leadership roles at Precision BioSciences and Shire. Barr brings expertise from Bridge Bio, where he managed significant capital raises. Cerio has a strong legal background from Moderna. The team aims to advance Atomwise's innovative drug discovery capabilities.

Precision BioSciences (Nasdaq: DTIL) announced that CEO Michael Amoroso will provide a corporate update at the annual J.P. Morgan Health Care Conference on January 12, 2022, from 2:15 - 2:55 PM ET. He will be joined by co-founder Derek Jantz, CFO Alex Kelly, and CMO Alan List for a Q&A session. The presentation will be available via a live webcast on the company's website, along with archived materials. Precision BioSciences is focused on developing innovative CAR T therapies using its proprietary ARCUS genome editing platform.

Precision BioSciences has announced an agreement with a syndicate led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary into an independent entity. This strategic move allows Elo to focus on food and agriculture, while Precision BioSciences can concentrate on human therapeutics utilizing its ARCUS® genome editing platform. Precision maintains an equity stake in Elo, and all employees transitioned to the new company. The separation aims to enhance operational success for both entities.

Precision BioSciences (DTIL) has reported promising updates on its allogeneic CAR T cell therapies, PBCAR0191 and PBCAR19B. In a Phase 1/2a study, PBCAR0191 showed a 73% overall response rate and a 59% complete response rate among heavily pre-treated patients. Notably, 100% of patients who had prior autologous CAR T therapy responded to PBCAR0191. The company is also progressing with PBCAR19B, which aims to be a best-in-class CD19 therapy. As of November 30, 2021, Precision holds approximately $152 million in cash, supporting operations into 2023.

Precision BioSciences, Inc. (DTIL) announced an upcoming webcast on December 11, 2021, at 7:30 PM ET to review interim data on the PBCAR0191 CD19 allogeneic CAR T program presented at the American Society of Hematology Annual Meeting. Key oral presentations include details on the efficacy of PBCAR0191 in relapsed/refractory B-cell malignancies, showcasing its therapeutic potential. The company aims to provide updates on its CAR T pipeline during this event, emphasizing its commitment to developing innovative gene editing therapies.

Precision BioSciences (NASDAQ: DTIL) announced the presentation of preclinical data on its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference in Cabo San Lucas, Mexico, from December 5-9, 2021.

The oral presentation, titled "Targeting Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo", is scheduled for December 6, 2021, at 11:25 AM ET. Preclinical research demonstrated that ARCUS technology reduced HBV s-antigen levels by 77% in infected human hepatocytes and achieved a durable 96% reduction in mouse models.

Precision BioSciences announced key leadership changes with Michael Amoroso appointed as President and CEO. The company is focusing on advancing its ARCUS gene editing platform, targeting three investigational new drug applications within three years. Financial results showed a revenue increase to $24 million for Q3 2021, up from $7.4 million in Q3 2020, primarily due to an agreement with iECURE. Despite increased R&D expenses at $25.9 million, the net loss narrowed to $11.3 million from $26 million year-over-year, showcasing operational progress.

Precision BioSciences (NASDAQ: DTIL) announced the acceptance of its abstract titled “Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine” for presentation at the SITC 36th Annual Meeting from November 10-14, 2021, in Washington, D.C. The study highlights a preclinical advancement using ARCUS gene editing to develop fludarabine-resistant CAR T cells, with a notable 70% reduction in dCK mRNA and improved tumor clearance in mice. The findings may enhance the potential of CAR T therapies in treating cancers resistant to conventional treatments.

Precision BioSciences (NASDAQ: DTIL) announced the addition of two experienced directors, Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D., to its Board. These appointments enhance the board's expertise in gene therapy and operational leadership. Dr. Wadsworth has nearly 30 years of experience in gene therapy development, while Ms. Piré brings extensive legal and business transformation skills. The company aims to advance three INDs/CTAs in the next three years, marking a significant phase in its growth strategy.